Skip to main content

Sustained Remissions After Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Sustained Remissions After Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

User login

Username

Password

Reset your password

Type	Lead	score